Iovance Biotherapeutics
IOVA
246 hedge funds and large institutions have $2.96B invested in Iovance Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 95 increasing their positions, 85 reducing their positions, and 34 closing their positions.
333% more call options, than puts
Call options by funds: $76.2M | Put options by funds: $17.6M
18% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 34
12% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 85
1% more funds holding
Funds holding: 243 → 246 (+3)
2.55% less ownership
Funds ownership: 101.91% → 99.36% (-2.5%)
24% less capital invested
Capital invested by funds: $3.88B → $2.96B (-$919M)
57% less funds holding in top 10
Funds holding in top 10: 7 → 3 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$51M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$26.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$19M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$97.9M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$31.4M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$31.2M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$31.2M |
| 5 |
PA
Perceptive Advisors
New York
|
-$30M |
IOVA Hedge Fund Activity: Q4 2021 in Review
246 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2021, worth a combined $2.96B — down 24% from $3.88B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new IOVA positions and 34 closed out — a net gain of 6 holders — while 95 added to existing stakes and 85 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $51M. The largest seller was ARK Investment Management, cutting an estimated $97.9M.
- 246 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2021, up from 243 in Q3 2021.
- Funds reported $2.96B of Iovance Biotherapeutics stock for Q4 2021, down 24% quarter-over-quarter.
- 40 funds opened new Iovance Biotherapeutics positions in Q4 2021 and 34 closed out, a net change of +6 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2021 was Avidity Partners Management, an estimated $51M added.
- The largest Iovance Biotherapeutics seller in Q4 2021 was ARK Investment Management, an estimated $97.9M sold.
Based on aggregated 13F filings for Q4 2021.